Phase II multi-center, non randomized open label study of Ipilimumab (anti CTLA-4) administered as first line monotherapy in adults patients with metastatic uveal melanoma [Ensayo clínico fase II, no randomizado, para evaluar el papel de Ipilimumab en monoterapia, administrado en primera línea en pacientes afectos de melanoma uveal metastásico]
Latest Information Update: 17 Jul 2015
At a glance
- Drugs Ipilimumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- Acronyms MelUv1
- 17 Oct 2011 Planned number of patients changed to 32.
- 17 Oct 2011 New trial record